Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuwellis, Inc. filings document a Nasdaq-listed medical technology issuer focused on cardiorenal care and ultrafiltration therapy. Form 8-K reports cover operating results, material events, clinical or regulatory disclosures, board appointments and resignations, and resolved litigation matters, while proxy materials describe director elections, auditor ratification, board committee governance, executive compensation, and stockholder voting matters.
Nuwellis, Inc. has completed its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology. This technology is designed to support clinical decision-making for critically ill patients, potentially broadening Nuwellis’ clinical offerings in advanced patient monitoring.
Nuwellis, Inc. files its annual report describing a small medical-device company focused on the Aquadex ultrafiltration system for cardiorenal fluid management. The business is concentrated in pediatrics, critical care and heart failure, with U.S. growth prioritized and most international operations exited.
The company discloses that existing cash only funds operations through the second quarter of 2026 and that additional capital is needed to operate through year-end 2026, raising substantial doubt about its ability to continue as a going concern. Nuwellis is outsourcing manufacturing to KDI Precision, investing in software upgrades and an NIH‑backed pediatric CRRT device, but also reports material weaknesses in internal controls.
Nuwellis, Inc. reported mixed fourth quarter and full year 2025 results. Q4 2025 revenue was $2.4 million, up 4% year over year and 9% sequentially, driven by stronger U.S. console sales and higher circuit pricing. Q4 gross margin improved to 68.2% from 58.4%, while operating loss was about $2.4 million, roughly flat with the prior-year quarter.
For full year 2025, revenue was $8.3 million, down 5% from 2024, with Heart Failure and Pediatrics growth offset by weaker Critical Care. Gross margin for the year was 62.0%. Net loss attributable to common shareholders was $17.5 million, including a $6.4 million non-cash warrant valuation expense and about $0.3 million of executive severance. As of December 31, 2025, Nuwellis had $1.2 million in cash, cash equivalents and restricted cash and no debt, after using $10.8 million of cash in operating activities and raising $6.9 million through equity financings during the year.
Nuwellis, Inc. director David McDonald reported his holdings of nonstatutory stock options in a Form 3. Following the reported positions, one option grant covers 7 underlying shares and another covers 416 underlying shares, both held directly. One option is fully vested and another vests in 12 approximately equal monthly installments.
Nuwellis, Inc. filed an initial ownership report for its Chief Financial Officer, Carisa Schultz. The Form 3 states that, as of the event date of 01/28/2026, no securities of Nuwellis are beneficially owned by the reporting person. An exhibit containing a Power of Attorney is attached.
Nuwellis, Inc. director Katharyn Field filed an initial ownership report on Form 3 stating that she currently has no beneficial ownership of Nuwellis securities. The filing confirms her status as a director and that, as of the reported event date, no company shares or derivatives are attributed to her.
Nuwellis, Inc. director Mika Grasso filed an initial ownership report stating that, as of 01/21/2026, no securities of Nuwellis are beneficially owned. The Form 3 lists no non-derivative or derivative holdings, indicating zero reported ownership at the time of the triggering event.
Nuwellis, Inc. is registering up to 4,279,325 shares of common stock for resale by existing security holders. These shares consist of stock issuable upon exercise of January 2026 pre-funded warrants, common stock purchase warrants, and placement agent warrants.
The company is not selling shares in this offering and will not receive proceeds from resale by the selling stockholders. Nuwellis will receive cash only if the related warrants are exercised for cash, which could total approximately $13.0 million if all warrants are fully exercised. Shares of common stock outstanding were 1,873,892 as of January 31, 2026, and would rise to 6,863,894 if all registered warrants are exercised.
The warrants generally have a strike price of $2.84 per share for investor warrants and $5.0985 per share for placement agent warrants, with holder beneficial ownership limited to 4.99%, or 9.99% upon notice. The filing highlights that substantial resales could pressure the stock price and that warrants may not be exercised if market prices stay below the exercise prices.